Cell BioEngines, a clinical-stage biotechnology company, has entered into an agreement with Miltenyi to develop and manufacture its expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology. Cell BioEngines’ stem cell expansion technology uses a small molecule to increase the number of hematopoietic stem cells derived from umbilical cord-blood while maintaining stemness, providing a “off-the-shelf” treatment for blood cancer patients who need a bone marrow transplant. Miltenyi will begin development towards Good Manufacturing Practices (GMP) manufacturing of Cell BioEngines’ CBE-101 clinical program. Miltenyi’s expertise in cell therapy process development and product scale-up makes them a perfect fit for GMP manufacturing of Cell BioEngines’ first clinical product candidate. The financial terms of the agreement were not disclosed.
Cell BioEngines, a clinical-stage biotech company, focuses on developing “off-the-shelf” allogenic cell therapies to make all cancers curable diseases. The company’s proprietary Stem-SPACE™ platform technology allows it to produce clinical-grade cells at large scales. Miltenyi Biotec, a global leader in biomedical research and cellular therapy, supports all stages of cell and gene therapy product development. Miltenyi’s platform technologies set industry standards in automated, integrated manufacturing and analysis of complex cellular products. The company has more than 4,700 employees in 23 countries and its products have been used in over 100,000 cell therapy procedures.